Legato Capital Management LLC Makes New $613,000 Investment in Rhythm Pharmaceuticals, Inc. $RYTM

Posted by Brenda Bartman on May 27th, 2026

Legato Capital Management LLC acquired a new position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) during the fourth quarter, HoldingsChannel reports. The fund acquired 5,723 shares of the company’s stock, valued at approximately $613,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in RYTM. AQR Capital Management LLC raised its position in shares of Rhythm Pharmaceuticals by 148.2% during the first quarter. AQR Capital Management LLC now owns 39,363 shares of the company’s stock worth $2,085,000 after acquiring an additional 23,506 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Rhythm Pharmaceuticals by 6.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,282 shares of the company’s stock worth $1,874,000 after acquiring an additional 2,126 shares during the last quarter. Prudential Financial Inc. raised its position in shares of Rhythm Pharmaceuticals by 62.9% during the second quarter. Prudential Financial Inc. now owns 7,095 shares of the company’s stock worth $423,000 after acquiring an additional 2,740 shares during the last quarter. Qube Research & Technologies Ltd raised its position in shares of Rhythm Pharmaceuticals by 11.2% during the second quarter. Qube Research & Technologies Ltd now owns 240,345 shares of the company’s stock worth $15,187,000 after acquiring an additional 24,152 shares during the last quarter. Finally, Sei Investments Co. raised its position in shares of Rhythm Pharmaceuticals by 10.0% during the second quarter. Sei Investments Co. now owns 33,145 shares of the company’s stock worth $2,095,000 after acquiring an additional 3,004 shares during the last quarter.

Analyst Upgrades and Downgrades

RYTM has been the subject of a number of recent research reports. Citizens Jmp dropped their target price on Rhythm Pharmaceuticals from $176.00 to $152.00 and set a “market outperform” rating for the company in a research report on Tuesday, March 17th. Zacks Research upgraded Rhythm Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 17th. Stifel Nicolaus set a $131.00 target price on Rhythm Pharmaceuticals in a research report on Thursday, February 26th. Telsey Advisory Group set a $143.00 target price on Rhythm Pharmaceuticals in a research report on Thursday, March 12th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Rhythm Pharmaceuticals in a research report on Tuesday, April 21st. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $131.81.

View Our Latest Report on Rhythm Pharmaceuticals

Rhythm Pharmaceuticals Trading Up 2.3%

NASDAQ RYTM opened at $89.82 on Wednesday. The stock has a 50-day simple moving average of $87.25 and a 200 day simple moving average of $97.41. The company has a market capitalization of $6.16 billion, a PE ratio of -28.70 and a beta of 1.94. Rhythm Pharmaceuticals, Inc. has a 12 month low of $58.71 and a 12 month high of $122.20.

Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.83) EPS for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.03. The business had revenue of $60.11 million during the quarter, compared to the consensus estimate of $55.78 million. Rhythm Pharmaceuticals had a negative return on equity of 203.25% and a negative net margin of 93.33%.The firm’s revenue was up 83.8% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.81) earnings per share. As a group, sell-side analysts predict that Rhythm Pharmaceuticals, Inc. will post -3.18 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CAO Christopher Paul German sold 5,614 shares of the company’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $89.56, for a total value of $502,789.84. Following the completion of the sale, the chief accounting officer owned 160 shares in the company, valued at approximately $14,329.60. This represents a 97.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 5.90% of the company’s stock.

Rhythm Pharmaceuticals Company Profile

(Free Report)

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.